Floatz logo

Cixutumumab

Bronchioloalveolar Lung Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bronchioloalveolar Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Barbara Ann Karmanos Cancer Institute
Phase 3BB
Gefetinib
National Cancer Institute (NCI)
Phase 3BB
Docetaxel
Wake Forest University Health Sciences
Phase 3BB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB
PEGFILGRASTIM
Wake Forest University Health Sciences
Phase 2B
Cetuximab
National Cancer Institute (NCI)
Phase 2B
Bortezomib
National Cancer Institute (NCI)
Phase 2B

Same molecule, other indications

Cixutumumab is also rated in:

Stage IV Breast Cancer AJCC v6 and v7Dormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →